{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:49:07Z","timestamp":1793638147777,"version":"4.5.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13555-026-01716-y","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:34:06Z","timestamp":1773934446000},"page":"2575-2585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM)"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06868212","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gil","family":"Yosipovitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle","family":"Mosnaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine-Elke","family":"Ortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Griswold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Mast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El-Djouher","family":"Martzloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"1716_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/all.70210","author":"T Zuberbier","year":"2026","unstructured":"Zuberbier T, Abdul Hameed Ansari Z, Abdul Latiff AH, et al. The international guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2026. https:\/\/doi.org\/10.1111\/all.70210.","journal-title":"Allergy"},{"issue":"12","key":"1716_CR2","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1111\/all.13209","volume":"72","author":"M Maurer","year":"2017","unstructured":"Maurer M, Abuzakouk M, B\u00e9rard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005\u201316.","journal-title":"Allergy"},{"issue":"8","key":"1716_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2025.101081","volume":"18","author":"W Soong","year":"2025","unstructured":"Soong W, Patil D, Rodrigues J, et al. Clinical profile, prevalence, and burden of chronic spontaneous urticaria in the United States. World Allergy Organ J. 2025;18(8):101081.","journal-title":"World Allergy Organ J"},{"issue":"3","key":"1716_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13555-025-01348-8","volume":"15","author":"K Weller","year":"2025","unstructured":"Weller K, Winders T, McCarthy J, et al. Urticaria Voices: real-world experience of patients living with chronic spontaneous urticaria. Dermatol Ther (Heidelb). 2025;15(3):747\u201361.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1716_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.anai.2024.11.028","volume":"134","author":"G Mosnaim","year":"2025","unstructured":"Mosnaim G, Patil D, Kuruvilla M, Hetherington J, Keal A, Mehlis S. Patient and physician perspectives on disease burden in chronic spontaneous urticaria: a real-world US survey. Ann Allergy Asthma Immunol. 2025;134(3):315\u201323.e3.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1716_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jaad.2019.02.064","volume":"81","author":"S Wertenteil","year":"2019","unstructured":"Wertenteil S, Strunk A, Garg A. Prevalence estimates for chronic urticaria in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2019;81(1):152\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1716_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13555-021-00641-6","volume":"12","author":"MM Balp","year":"2022","unstructured":"Balp MM, Halliday AC, Severin T, et al. Clinical remission of chronic spontaneous urticaria (CSU): a targeted literature review. Dermatol Ther (Heidelb). 2022;12(1):15\u201327.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1716_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1046\/j.1365-2133.2002.04582.x","volume":"146","author":"PG van der Valk","year":"2002","unstructured":"van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol. 2002;146(1):110\u20133.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1716_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4168\/aair.2018.10.1.83","volume":"10","author":"YS Kim","year":"2018","unstructured":"Kim YS, Park SH, Han K, et al. Clinical course of chronic spontaneous urticaria in the Korean adult population. Allergy Asthma Immunol Res. 2018;10(1):83\u20137.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"5","key":"1716_CR10","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","volume":"153","author":"JA Bernstein","year":"2024","unstructured":"Bernstein JA, Maurer M, Saini SS. BTK signaling\u2014a crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2024;153(5):1229\u201340.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1716_CR11","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","volume":"139","author":"P Kolkhir","year":"2017","unstructured":"Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772\u201381.e1.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1716_CR12","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.jaci.2014.02.036","volume":"133","author":"JA Bernstein","year":"2014","unstructured":"Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"1716_CR13","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s13555-025-01461-8","volume":"15","author":"JA Bernstein","year":"2025","unstructured":"Bernstein JA, Winders TA, McCarthy J, et al. Urticaria Voices: real-world treatment patterns and outcomes in chronic spontaneous urticaria. Dermatol Ther (Heidelb). 2025;15(8):2201\u201315.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1716_CR14","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/bjd.14768","volume":"175","author":"S Guill\u00e9n-Aguinaga","year":"2016","unstructured":"Guill\u00e9n-Aguinaga S, J\u00e1uregui Presa I, Aguinaga-Ontoso E, Guill\u00e9n-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1153\u201365.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1716_CR15","first-page":"1091","volume":"99","author":"S Goldstein","year":"2019","unstructured":"Goldstein S, Eftekhari S, Mitchell L, et al. Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US. Acta Derm Venereol. 2019;99(12):1091\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"1716_CR16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1056\/NEJMoa2408792","volume":"392","author":"M Metz","year":"2025","unstructured":"Metz M, Gim\u00e9nez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984\u201394.","journal-title":"N Engl J Med"},{"key":"1716_CR17","unstructured":"Novartis Pharmaceuticals Corporation. Highlights of prescribing information: RHAPSIDO\u00ae (remibrutinib) tablets, for oral use. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/rhapsido.pdf. Accessed 15 Oct 2025."},{"issue":"5","key":"1716_CR18","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204.","journal-title":"Allergy"},{"issue":"1","key":"1716_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184\u201394.","journal-title":"J Allergy Clin Immunol"},{"issue":"6 Suppl 2","key":"1716_CR20","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.anai.2024.10.005","volume":"133","author":"T Casale","year":"2024","unstructured":"Casale T, Saini S, Bernstein J, et al. Dupilumab significantly improves itch and hives in patients with chronic spontaneous urticaria (CUPID study C). Ann Allergy Asthma Immunol. 2024;133(6 Suppl 2):S2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1716_CR21","unstructured":"Regeneron Pharmaceuticals Inc. Highlights of prescribing information: DUPIXENT\u00ae (dupilumab) injection, for subcutaneous use. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf. Accessed 15 Oct 2025."},{"issue":"9","key":"1716_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","volume":"22","author":"P Kolkhir","year":"2023","unstructured":"Kolkhir P, Akdis CA, Akdis M, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov. 2023;22(9):743\u201367.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"1716_CR23","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/cts.13005","volume":"14","author":"M Kaul","year":"2021","unstructured":"Kaul M, End P, Cabanski M, et al. Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci. 2021;14(5):1756\u201368.","journal-title":"Clin Transl Sci"},{"issue":"S114","key":"1716_CR24","first-page":"S140","volume":"80","author":"J Reed","year":"2025","unstructured":"Reed J, Lebwohl M, Jain V, et al. Remibrutinib improves chronic spontaneous urticaria independent of baseline immunoglobulin E levels in the phase 3 REMIX studies. Allergy. 2025;80(S114):S140\u20131.","journal-title":"Allergy"},{"issue":"9","key":"1716_CR25","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s13555-024-01231-y","volume":"14","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, et al. Dupilumab reduces urticaria activity, itch, and hives in patients with chronic spontaneous urticaria regardless of baseline serum immunoglobulin E levels. Dermatol Ther. 2024;14(9):2427\u201341.","journal-title":"Dermatol Ther"},{"issue":"5, Supplement 1","key":"1716_CR26","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.anai.2025.08.035","volume":"135","author":"S Saini","year":"2025","unstructured":"Saini S, Mosnaim G, Sussman G, et al. Efficacy of remibrutinib in anti-IgE biologic-na\u00efve, biologic-experienced, and biologic-refractory patients with CSU: REMIX-1\/-2 studies. Ann Allergy Asthma Immunol. 2025;135(5, Supplement 1):S8\u20139.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01716-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01716-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01716-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:18:28Z","timestamp":1779949108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01716-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1716"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01716-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gil Yosipovitch has received funding\/grants from Celldex, Eli Lilly, Escient Health, Kiniksa, Novartis, Pfizer, Regeneron, and Sanofi; has received consulting support from AbbVie, Arcutis, Eli Lilly, Escient Health, Galderma, Kamari, Kiniksa, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi, Trevi Therapeutics, and Vifor; has received honoraria from Maruho; has participated in advisory boards for AbbVie, Eli Lilly, Escient Health, Galderma, GSK, Kamari, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi, Trevi Therapeutics, and Vifor; and holds patents for Topical Acetaminophen Formulations for Itch Relief. Gil Yosipovitch is an Editorial Board member of\n                      Dermatology and Therapy.\n                      Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Giselle Mosnaim serves on the AAAAI\/ACAAI JTFPP Steering Committee; receives current research grant support from Areteia, Celldex, Genentech, GlaxoSmithKline, Incyte, Merck, Novartis, Regeneron, Sanofi, and Teva; and receives consulting, advisory board, and\/or speaking fees from Chiesi, Genentech, Jasper, Novartis, Regeneron, Sanofi, and Teva. Christine-Elke Ortmann and El-Djouher Martzloff are employees of Novartis Pharma AG, Basel, Switzerland. Nicole Griswold, Jane Mast, and Jonathan Rodrigues are employees of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Jason E. Hawkes has served as an advisor, consultant, speaker, investigator, and\/or medical board member for AbbVie, Acelyrin, Allakos, Alumis, Amgen, Apogee, Arcutis, Boehringer Ingelheim, Blueprint Medicines, Bristol Myers Squibb, Celldex, Dermavant, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, National Psoriasis Foundation, Novartis, Oruka, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was designed and will be implemented, executed, and reported in accordance with consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) international ethical guidelines, applicable International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Tripartite Guidelines for Good Clinical Practice (GCP), and other applicable local regulations. All study patients will be required to sign a statement of informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}